Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity

Selumetinib was recently approved for the treatment of inoperable symptomatic plexiform neurofibromas (PNs) in children with neurofibromatosis type 1 (NF1). This parallel phase II study determined the response rate to selumetinib in children with NF1 PN without clinically significant morbidity. Chil...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2022-11, Vol.24 (11), p.1978-1988
Hauptverfasser:	Gross, Andrea M, Glassberg, Brittany, Wolters, Pamela L, Dombi, Eva, Baldwin, Andrea, Fisher, Michael J, Kim, AeRang, Bornhorst, Miriam, Weiss, Brian D, Blakeley, Jaishri O, Whitcomb, Patricia, Paul, Scott M, Steinberg, Seth M, Venzon, David J, Martin, Staci, Carbonell, Amanda, Heisey, Kara, Therrien, Janet, Kapustina, Oxana, Dufek, Anne, Derdak, Joanne, Smith, Malcolm A, Widemann, Brigitte C
Format:	Artikel
Sprache:	eng
Schlagworte:	Benzimidazoles - therapeutic use Child Humans Morbidity Neurofibroma, Plexiform - pathology Neurofibromatosis 1 - pathology Pain - etiology Pediatric Neuro-Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!